Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Automated Insulin for Management of Intrapartum Glycemia

NCT: NCT06883344 · RECRUITING

NCT IDNCT06883344
StatusRECRUITING
Start Date2025-12-05
Completion2028-12-31

Brief Summary

The goal of this clinical trial is learn if automated insulin delivery (AID) systems can be used for glucose management during labor/delivery for pregnant people with type 1 diabetes (T1D). The main questions this study aims to answer are * What are the neonatal glycemic outcomes with use of AID systems during labor/delivery? * Do patients report higher birth satisfaction with use of AID systems during labor/delivery? * Are glycemic parameters like time-in-range (TIR) better with use of AID systems during labor/delivery? Researchers will compare AID systems to intravenous (IV) insulin (the current standard of care for glucose management during labor/delivery) by randomly assigning participants to one or the other.

Frequently Asked Questions

What is Automated Insulin for Management of Intrapartum Glycemia?

Automated Insulin for Management of Intrapartum Glycemia is a clinical trial registered under NCT06883344. Current status: RECRUITING.

What is the status of NCT06883344?

The current status of NCT06883344 (Automated Insulin for Management of Intrapartum Glycemia) is: RECRUITING.

When did Automated Insulin for Management of Intrapartum Glycemia start?

Automated Insulin for Management of Intrapartum Glycemia started on 2025-12-05.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.